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Abstract
The objective of this study was to determine the association between weight loss and drug-induced hepatotoxicity (DIH). A retrospective
observational study of 192 active tuberculosis (TB) patients consecutively admitted in a tertiary referral TB centre in the Netherlands was
conducted. The outcome measure for DIH was defined as hepatotoxicity necessitating interruption of anti-TB drugs. Multivariate logistic
regression analysis on interruption of anti-TB drugs was performed, with age, sex, nutritional status, TB disease severity, drug resistance,
comorbidity including baseline liver function tests, anti-TB drug regimen, co-medication and addictions as independent risk factors.
Anti-TB drugs were interrupted in thirty-one patients (16·1 %). The most important risk factor was weight loss of 2 kg or more within 4
weeks during TB treatment (OR 211, 95 % CI 36·0, 1232). Other independent risk factors were infection with hepatitis C (OR 19·6, 95 %
CI 2·4, 164), age over 60 years (OR 18·5, 95 % CI 2·3, 151) and multi-drug-resistant TB (OR 8·2, 95 % CI 1·3, 53·6). This study shows
that weight loss during TB treatment was the most important risk factor for DIH necessitating interruption of anti-TB drugs. Causes of
weight loss during TB treatment and the association between weight change and hepatotoxicity need further investigation.
Key words: Malnutrition: Weight loss: Risk factors: Drug-induced hepatotoxicity: Tuberculosis
Drug-induced hepatotoxicity (DIH) is a well-known
complication in the treatment of tuberculosis (TB). This
may sometimes require interruption of therapy with anti-
TB drugs. Incidence of hepatotoxicity during treatment of
TB disease varies from 5 to 33 %. It depends on the study
population, definition of hepatotoxicity, anti-TB drugs
used, and the way of monitoring(1). Many factors have
been associated with DIH. These include TB morbidity(2–5),
co-infections such as HIVand hepatitis B and C(6–12), malnu-
trition(4,13), old age(14), female sex(2,4,15), elevated transamin-
ases at baseline(14,16–18), and high alcohol intake(3,6).
Malnutrition, as assessed by a low BMI, has been associ-
ated with the occurrence of TB-DIH in two studies(4,13).
BMI at the start of TB treatment is a frequently used
static nutritional risk factor in TB research(19,20). Body
weight (BW) change after the start of TB treatment may
reflect an improving or a worsening nutritional status
during TB treatment. In this study we intended to assess
the link between this BW change and drug-induced liver
toxicity necessitating interruption of anti-TB drugs.
Methods
Patients
A retrospective review of patients records, admitted
between January 2005 and July 2008 at TB Centre Beatrix-
oord of University Medical Center Groningen, Netherlands,
was conducted. All patients . 14 years of age diagnosed
with active Mycobacterium tuberculosis infection(21) were
included. Interrupters were patients who had to stop one
or more anti-TB drugs for reasons of hepatotoxicity
based on international guidelines(1,22).
Controls (non-interrupters) were all other patients
admitted during the same study period. The following
data about the cases were collected: age, sex, addictions,
time to interruption, nutritional status, morbidity,
*Corresponding author: I. Warmelink, fax þ31 50 5338650, email g.warmelink@cvr.umcg.nl
Abbreviations: BW, body weight; DIH, drug-induced hepatotoxicity; HBV, hepatitis B virus; HCV, hepatitis C virus; MDR-TB, multi-drug-resistant
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medication and drug sensitivity test results. Because this
was a retrospective chart review with anonymised report-
ing, approval by the ethics committee was not required.
Nutritional status
Nutritional status was defined by BW change. BW gain after
the start of anti-TB drugs was classified as a gain $ 2 kg
within 4 weeks after the start of anti-TB drugs. Weight loss
was defined as a decrease in BW $ 2 kg within 4 weeks
after the start of anti-TB drugs. If either weight gain or loss
was , 2 kg, BW was considered as stable. If anti-TB drugs
were interrupted after more than 4 weeks of treatment, the
BW data of the 4 weeks before interruption were used to
assess the nature of BW change.
Medication
Gradual introduction of anti-TB drugs at the start of treat-
ment was defined as an increasing day dose over time or
sequential introduction of the drugs. If anti-TB drugs were
administered for at least 2 weeks, medication was classified
into three possible anti-TB drugs schedules: (1) isoniazid
(H), rifampicin (R), pyrazinamid (Z), ethambutol (E); (2)
HRZ; (3) other, including drugs for multi-drug-resistant TB
(MDR-TB). Day dose was defined as the highest dose of
anti-TB drugs in mg per kg baseline BW that had been admi-
nistered for at least 2 weeks. If interruption of anti-TB drugs
occurred within the first 2 weeks of treatment, the day dose
was defined as the highest dose given until interruption.
Co-medication administered to anti-TB treatment was classi-
fied into no, low or high risk for DIH(23).
Tuberculosis morbidity
Patients were classified based on the severity of TB using
WHO criteria(21). Classifications were performed indepen-
dently by two lung specialists. In case of discordance,
cases were reviewed and final classifications were reached
by consensus.
Comorbidity
The effect of comorbidity on hepatotoxicity was assessed
by applying the Charlson Comorbidity Index(24,25). Infec-
tion due to the hepatitis B virus (HBV), hepatitis C virus
(HCV) and HIV were noted as autonomous morbidity
and not included in the Charlson Comorbidity Index.
HBV, HCV and HIV status were listed positive if medical
files noted presence of HBV surface antigen, HCV anti-
bodies and HIV antibodies, respectively.
Statistical analysis
SPSS for Windows (version 16.0; SPSS, Inc., Chicago, IL,
USA) was used for all statistical analyses. Differences in
categorical variables between interrupters and non-
interrupters were compared using Pearson’s x 2 test, or
Fisher’s exact test for dichotomous variables. Differences in
parametric variables were assessed by Student’s unpaired
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192 patients eligible for analysis
  Thirty-one patients (16·1 %) had interruption
of anti-TB drugs 
  161 patients (83·9 %) had no interruption
of anti-TB drugs
Outcome of twenty-six excluded patients
  Three patients (11·5 %) had interruption
of anti-TB drugs based on hepatotoxicity
  Four patients (15·4 %) died during admission
218 patients meeting inclusion criteria
Fig. 1. Flow diagram of study subjects. TB, tuberculosis.
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t test, and in non-parametric variables by the Mann–Whitney
U test. All the statistical tests were two sided, and a
P-value,0·05 was considered statistically significant.
Variables associated with interruption at a P-value,0·1 in
the monovariate analysis and variables that were considered
relevant in previous TB hepatotoxicity studies were analysed
using multivariate logistical regression. Using the enter
method we aimed for a final multivariate model containing
the least possible variables that explained the most – the
parsimonious model. Cox proportional hazards regression
analysis was used to evaluate the simultaneous effect of
different variables on time to interruption during TB
treatment. Time to interruption in days was measured from
the day of start of anti-TB drugs until the day of interruption.
Non-interrupters were censored at 300 d counted from the
start of anti-TB drugs. Kaplan–Meier hazard curves were
generated for the primary outcome.
Results
Study population
Of the 218 patients admitted during the study period,
twenty-six (11·9 %) were excluded from the analysis; the
reasons are given in the flow diagram (Fig. 1). Of the
remaining 192 patients, thirty-one (16·1 %) developed
hepatotoxicity, necessitating interruption of anti-TB drugs.
Demographic data
There were 148 (77·1 %) males. The median age of the
study population was 38 (range 16–84) years. Patients
with interruption of anti-TB drugs were comparable in
age, sex, origin, history of alcohol abuse and smoking
to non-interrupters. More patients with a history of
drug abuse were observed among the non-interrupters
(Table 1).
Nutritional status
A majority of 163 patients (85·3 %) reported BW loss before
the start of treatment v. twenty-six patients (13·6 %) who
reported no BW change, and two patients (1·0 %) who
reported BW gain. The reported BW change before the
start of TB treatment was not significantly different
between interrupters (212·6 %, SD 7·1) and non-interrup-
ters (215·0 %, SD 11·1). BMI at the start of treatment did
not show any significant difference between interrupters
and non-interrupters either. During TB treatment twenty-
eight patients (14·6 %) lost BW, sixty-four patients
(33·3 %) gained weight and 100 patients (52·1 %) had a
stable BW (Table 1).
Medication
The interrupters and non-interrupters were comparable
in all medication characteristics studied, except for the
pyrazinamid dose and the number of patients above the
recommended upper BW dose of pyrazinamid, which
were both lower for the interrupters(26). In the interrupters,
BMI was significantly lower and BW doses higher after
interruption (Table 2).
Table 1. Patient characteristics†
(Mean values and standard deviations; numbers and percentages)
Interrupters
(n 31, 16·1 %)
Non-interrupters
(n 161, 83·9 %)
Mean/n SD/% Mean/n SD/% P
Age (years) 43·7 19·8 39·0 15·9 0·317
Female 8 25·8 36 22·4 0·676
Origin 0·865
Europe 13 41·9 55 34·2
Mediterranean countries‡ 2 6·5 14 8·7
Sub-Saharan Africa 11 35·5 54 33·5
Asia 3 9·7 23 14·3
South America 2 6·5 15 9·3
Abuse of alcohol (n 191) 12 38·7 55 34·4 0·683
Abuse of drugs (n 191)§ 2 6·5 48 30·0 0·006**
History of smoking (n 173) 14 63·6 99 65·6 1·000
Weight (kg) 61·2 10·0 59·8 13·3 0·368
BMI (kg/m2) 20·8 3·5 20·2 4·0 0·339
Weight change after start anti-TB drugs ,0·001***
Weight loss $ 2 kg 22 71·0 6 3·7
Stable weight 8 25·8 92 57·1
Weight gain $ 2 kg 1 3·2 63 39·1
TB, tuberculosis.
Values were significantly different: **P,0·01; ***P,0·001.
† The number of analysed/tested patients is 192, unless otherwise specified.
‡ Mediterranean countries: patients originated from Morocco, and Turkey.
§ Drugs abuse of cocaine, heroine, marijuana.
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Morbidity and tuberculosis drug susceptibility
Both the groups were comparable in disease severity,
comorbidity, baseline transaminases, TB drug susceptibility
of M. tuberculosis isolates. Only the proportion of HIV-
positive patients was significantly higher among the inter-
rupters than among the non-interrupters (Table 3).
Independent risk factors for interruption
BW loss after the start anti-TB drugs, HCV infection,
age . 60 years and presence of MDR-TB were significant
independent risk factors for interruption in a multivariate
model. Sex and age were forced into this multivariate
model. Age as a continuous variable did not prove linearity
in classes of 10 years, therefore we decided to enter the
variable of age into two classes (.60 and # 60 years),
based on the results from prior publications(27,28). HBV
infection, abnormal baseline aspartate transaminase and
drug abuse were not independent risk factors for interrup-
tion. These three factors did not contribute to the signifi-
cance of the other independent risk factors either. For
these two reasons they were not added to the final multi-
variate model. HIV infection was not an independent risk
factor for interruption either, nor was it a confounder as
it did not alter the main risk factor of interest (weight
loss after the start of anti-TB drugs) for more than 10 %
of the adjusted OR. For explanatory reasons, HIV infection
was kept in the final model. Results of univariate and multi-
variate analysis for risk factors for interruption in time are
shown in Table 4.
Time to interruption
The median time to interruption was 15 (range 3–270) d.
Significant adjusted hazard ratios for time to interruption
Table 2. Medication characteristics†
(Mean values and standard deviations; numbers and percentages)
Interrupters
(n 31, 16·1 %)
Non-interrupters
(n 161, 83·9 %)
Mean/n SD/% Mean/n SD/% P
Gradual introduction of anti-TB drugs (n 191) 0·363
Yes 5 16·1 39 24·4
No 26 83·9 121 75·6
Anti-TB drugs schedule 0·197
HRZE 21 67·7 109 67·7
HRZ 4 12·9 8 5·0
Other‡ 6 19·4 44 27·3
H (mg/kg, n 175) 5·1 0·9 5·2 1·1 0·546
R (mg/kg, n 172) 9·9 1·6 10·3 2·0 0·251
Z (mg/kg, n 170) 28·1 3·0 30·1 3·7 0·003**
E (mg/kg, n 159) 22·0 4·1 20·6 3·1 0·129
Co-medication 0·970
No use or no risk for DIH 18 58·1 97 60·2
Low risk for DIH 10 32·3 50 31·1
High risk for DIH 3 9·7 14 8·7
Above the upper body weight dose
H body weight dose .6 mg/kg (n 175) 4 16·0 31 20·7 0·788
R body weight dose .12 mg/kg (n 172) 3 12·5 25 16·9 0·770
Z body weight dose .30 mg/kg (n 170) 7 25·0 79 55·6 0·004**
E body weight dose . 20 mg/kg (n 159) 14 66·7 77 55·8 0·478
At start treatment
BMI (kg/m2, n 31)§ 20·8 3·5 0·003**
Body weight dose (mg/kg)§
H (n 25) 5·1 0·9 0·001**
R (n 24) 9·9 1·6 ,0·001***
Z (n 28) 28·1 3·0 0·002**
E (n 21) 22·0 4·1 0·006**
After interruption
BMI (kg/m2, n 31)§ 20·0 3·4 0·003**
Body weight dose (mg/kg)§
H (n 25) 5·3 0·8 0·001**
R (n 24) 10·4 1·5 ,0·001***
Z (n 28) 29·7 3·4 0·002**
E (n 21) 23·0 3·8 0·006**
TB, tuberculosis; H, isoniazid; R, rifampicin; Z, pyrazinamid; E, ethambutol; DIH, drug-induced hepatotoxicity.
Values are significantly different: **P,0·01; ***P,0·001.
† The number of analysed/tested patients is 192, unless otherwise specified.
‡ Other, the anti-TB drugs schedule consists other than the sets HRZE or HZE, with the following drugs: amikacin, capreomycin,
clarithromycin, clofazimine, cycloserine, doxycycline, ethambutol, isoniazid, levofloxacin, linozelid, moxifloxacin, prothionamide,
pyrazinamide, rifabutin, rifampicin, thioacetazone.
§ The Wilcoxon signed-rank test was used to compare BMI and body weight doses at the start of treatment with those after interruption.
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were age . 60 years, BW loss, and HIV- and HCV-infec-
tions, and are presented in Table 4. For a patient at the
start of TB treatment, the cumulative hazard of interrupting
anti-TB drugs within 60 d was 0·034 (Fig. 2(a)). The cumu-
lative hazard for patients interrupting anti-TB drugs
between 60 and 270 d after the start of TB treatment was
0·058 2 0·034 ¼ 0·024. The adjusted hazard ratio for HIV-
positivity was 4·2 (95 % CI 1·40, 12·9) (Table 4, Fig. 2(b)).
Interrupters who lost BW discontinued their anti-TB
drugs predominantly in the beginning of treatment: 67 %
of those loosing BW interrupted anti-TB drugs within the
first 15 d of treatment, v. 33 % after 15 d (P¼0·046,
Table 5, Fig. 3(a)). In contrast, all interrupters who were
HCV-positive discontinued their anti-TB drugs after 30 d
(P¼0·023; Table 5, Fig. 3(b)). All the interrupters who
were MDR-TB patients had to discontinue their anti-TB
drugs after 30 d of TB treatment too (P¼0·009; Table 5).
Discussion
This retrospective study demonstrated that TB treatment
had to be interrupted due to DIH in 16·1 % of the admitted
TB patients. Weight loss after the start of anti-TB drugs,
HCV infection, age . 60 years and MDR-TB were indepen-
dent and significant risk factors for interruption. The
median time to interruption was 15 (range 3–270) d, and
73 % of the interrupters had to discontinue anti-TB drugs
within the first 60 d of TB treatment.
This is the first report to show that weight loss of 2 kg or
more, developed within 4 weeks during TB treatment,
appears to be a highly significant independent risk factor
for TB-DIH. Other nutritional factors such as self-reported
weight loss before treatment and BMI at the start were not
associated with interruption.
In most patients (85·4 %) in this study BW stabilized or
increased during treatment, whereas a small proportion
(14·6 %) demonstrated weight loss. Not the BMI at the
start of treatment, but the ability to adequate food intake
seems to be important during treatment. To our knowl-
edge, research on factors associated with weight loss
during TB treatment has not been performed yet. We
suggest that side effects of anti-TB drugs, such as gastroin-
testinal symptoms, which are relatively common in the first
few weeks of TB treatment(29) may result in inadequate
food intake(30) and might cause weight loss if gastrointesti-
nal symptoms persist or worsen. Indeed gastrointestinal
symptoms have been identified as risk factors for predomi-
nantly early interruptions(31), which is in line with weight
loss-associated early interruptions in this study (Fig. 3(a),
Table 5).
AIDS as a comorbidity might add to weight loss during
TB treatment. In this study the BMI at the start of TB treat-
ment was not different between HIV-positive patients and
non-HIV positive patients. However, self-reported weight
loss noted as the percentage of the normal BW before dis-
ease was significantly higher in HIV-positive patients
(21·2 %) than in the non-HIV-positive patients (14·0 %).
This weight loss before TB treatment might have caused
associated illness and disability to adequate food intake
for sustaining or increasing BW during TB treatment in
AIDS patients.
Table 3. Morbidity, comorbidity and tuberculosis (TB) drug susceptibility†
(Mean values and standard deviations; numbers and percentage)
Interrupters
(n 31, 16·1 %)
Non-interrupters
(n 161, 83·9 %)
Mean/n SD/% Mean/n SD/% P
WHO TB classification 0·329
Extra pulmonary TB 1 (most severe) 11 35·5 37 23·0
Pulmonary TB 19 61·3 116 72·0
Extra pulmonary TB 2 (least severe) 1 3·2 8 5·0
HBV-pos‡ 1 5·6 2 3·9 1·000
HCV-pos‡ 4 22·2 7 13·2 0·453
HIV-pos‡ 6 25·0 9 6·4 0·011*
Charlson Comorbidity Index
Unadjusted for age 0·48 0·81 0·32 0·68 0·218
Adjusted for age 1·1 1·9 0·6 1·3 0·179
Baseline AST (IU/l, n 183) 53·3 63·3 36·4 37·6 0·075
Baseline ALT (IU/l, n 183) 27·7 15·4 30·3 37·1 0·507
TB drug susceptibility of Mycobacterium tuberculosis isolates (n 160)§ 0·143
Normal susceptibility 20 76·9 121 90·3
Mono-drug resistance 1 3·8 3 2·2
Multi-drug resistance 5 19·2 10 7·5
HBV, hepatitis B virus; pos, positive; HCV, hepatitis C virus; AST, aspartate transaminase; ALT, alanine transaminases.
* P,0·05.
† The number of analysed/tested patients is 192, unless otherwise specified.
‡ Untested patients with: HBV status n 123; HCV status n 121; HIV status: n 28.
§ Untested patients with TB drug susceptibility of strains (n 32).
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An adequate intake of nutrients is important for the
integrity of liver metabolism and detoxicification of TB
drugs, as the cytochrome P-450 enzyme system is affected
by nutrient intake and fasting(32).
Although BW doses of anti-TB drugs were higher after
interruption due to weight loss compared to the start of
TB treatment (Table 2), we do not consider these higher
doses relevant for the development of DIH. There was
no difference between interrupters and non-interrupters
with regard to BW doses above the recommended upper
BW dose of isoniazid and rifampicin(26). Moreover, a sig-
nificantly smaller part of interrupters received BW doses
of pyrazinamid above the recommended upper BW dose
than non-interrupters.
Interrupters who were HCV-positive patients had to
interrupt their treatment after 30 d of treatment, in contrast
to those with BW loss who had to interrupt early. This may
be caused by a delayed inflammatory immune response
against HCV occurring only after several weeks of TB treat-
ment, resulting in hepatic cell damage. At the start of TB































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Time since start of anti-TB drugs (d)
150 200 300250
Fig. 2. (a) Cox proportional hazard function of a patient at mean of
covariates. (b) Cox proportional hazard function for the HIV status. TB,
tuberculosis. , No HIV; , HIV; , not tested for HIV.
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liver cells is probably suppressed as a result of untreated
TB and associated malnourishment. Shortly after the intro-
duction of successful treatment the inflammatory immune
response may restore and target the HCV-infected liver
cells. An immune reactivation to HCV during TB treatment
with interruption of anti-TB drugs as a result has not been
described before and needs further investigation.
Age above 60 years was an independent risk factor for
DIH in our model; this has been reported earlier(14).
Increased susceptibility for hepatotoxicity with higher age
could be partly due to physiological changes. Intravascular,
organ, muscle and distribution volumes are usually smaller
in the elderly(33), which might result in depressed hepatic
drug metabolism and elimination, particularly of drugs
metabolised by the cytochrome enzyme system(34,35).
Another mechanism may be that elderly people have a
reduced food intake(36), causing lower availability of nutri-

















































































































































































































































































































































































































































































































































































Time since start of anti-TB drugs (d)
150 200 300250
Fig. 3. Kaplan–Meier curve of the hazard for interruption of (a) weight
change after start TB treatment and (b) hepatitis C status. TB, tuberculosis;
HCV, hepatitis C virus. (a) , Weight loss; , stable weight;
, weight gain. (b) , No HCV; , HCV; , not
tested for HCV.
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MDR-TB as an independent risk factor for TB-DIH has
not been reported earlier. MDR-TB treatment lasts longer
(typically 18–24 months) and requires drugs which are
more toxic than standard treatment drugs for TB. Toxicity
developed relatively late (Table 5), and this might reflect
immune enhancement as discussed above.
Interruption of anti-TB drugs because of hepatotoxicity
typically occurred within the first 2 months of treatment.
This is in accordance with other TB-DIH studies(4,5,14,37).
The cumulative hazard for interruption was highest
during the first 60 d of treatment (Fig. 2(a)). Concerning
the identified factors for interruption, 66·7 % of the
weight-losing interrupters had to interrupt anti-TB drugs
within the first 15 d of treatment v. 33·3 % after 15 d of
treatment (P¼0·046; Table 5; Fig. 3(a)). In contrast, all the
HCV-infected and all MDR-TB interrupters had to stop
anti-TB drugs after 30 d of treatment (Fig. 3(b), Table 5). To
our knowledge this is the first study identifying risk factors
for TB-DIH related with time to interruption.
In contrast to other studies, neither HIV(11,12) nor HBV
co-infection(8,10) were identified as independent risk fac-
tors, but in the studied population only three patients
(1·2 %) had HBV. Although HIV infection was not identified
as a risk factor, a significant hazard ratio of 4·2 for interrup-
tion of HIV-positivity was found. This hazard ratio implies
that the simultaneous effects of risk factors of the HIV-
positive patients together exerted a hazard over time to
cause interruption (Fig. 2(b)). Because in five of the six
HIV-positive interrupters weight loss was identified, we
speculate that weight loss is an important risk factor for
HIV-positive patients in TB-DIH.
In contrast to other studies(2–5), severity of TB disease
was not associated with hepatotoxicity. Of the 192 patients,
most (70·3 %) were classified in the pulmonary TB class.
This large class of pulmonary TB probably included
patients with a very broad range of clinical disease severity,
decreasing the possible association between the disease
severity and interruption.
The strength of the study is the heterogeneous study
population with many risk factors for hepatotoxicity. The
limitations of the study are the retrospective design and
the primary outcome measure of interruption which is
not based on strictly defined criteria.
Interruption of treatment of TB prolongs treatment,
increasing the social and economic burden for the patient
and the community. This study shows that weight loss was
the most important risk factor. Prospective studies are
urgently needed to assess the cause-and-effect relationship
between weight loss and an evolving DIH during TB
treatment.
In conclusion, weight loss of 2 kg or more during TB
treatment was a significant independent risk factor for
interruption of anti-TB drugs. For interruption, which
occurs predominantly within the first 60 d of TB treatment,
HCV infection, age . 60 years and MDR-TB were also
identified as significant risk factors.
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